Functional imaging in liver tumours
Functional imaging encompasses techniques capable of assessing physiological parameters of tissues, and offers useful clinical information in addition to that obtained from morphological imaging.
Exercise in NAFLD: Just do it
The health burden of non-alcoholic fatty liver disease (NAFLD) is multifaceted. In addition to sequelae of end-stage liver disease and hepatocellular carcinoma, the deleterious role of hepatic steatosis in the development of type 2 diabetes and cardiovascular disease is also well established.
Direct Acting Antiviral Therapy and Tumor Recurrence after Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma
We read with great interest the article by Reig et al., published in Journal of Hepatology, which reported the impact of direct acting antivirals (DAA) on the risk of hepatocellular carcinoma (HCC) recurrence after achievement of complete radiological response by resection, ablation or chemoembolization.
Long-Term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer
The incidence of hepatocellular carcinoma (HCC) increases with age, but protective antibody responses decrease with time after infants are immunized against hepatitis B virus (HBV). We investigated whether immunization of infants against HBV prevents against their development of HCC as adults. We also searched for strategies to maximize the cancer-preventive effects.
Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis
Direct-acting antivirals have become widely used for patients with chronic hepatitis C virus infection with decompensated cirrhosis. Virological responses are excellent and early improvements in liver function, at least in a proportion of patients, have been observed but the longer term impact of viral clearance on end-stage liver disease complications is unclear.
“Aiming for cure in HBV and HDV infection”
Chronic hepatitis B virus (HBV) infection continues to be a major health burden worldwide. Currently available antiviral treatment options for chronic hepatitis B include pegylated interferon alpha2a (PEG-IFN) or nucleos(t)ide analogues (NAs).
Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound
Hepatitis B virus (HBV) RNA in serum has recently been linked to efficacy and prognosis of chronic hepatitis B (CHB) treatment. This study explored the nature, origin, underlying mechanisms, and potential clinical significance of serum HBV RNA.
EpCAM-Regulated Intramembrane Proteolysis Induces a Cancer Stem Cell-like Gene Signature in Hepatitis B Virus-infected Hepatocytes
Hepatocytes in which the hepatitis B virus (HBV) is replicating exhibit loss of the chromatin modifying Polycomb Repressive Complex 2 (PRC2), resulting in re-expression of specific, cellular PRC2-repressed genes. Epithelial Cell Adhesion Molecule (EpCAM) is a PRC2-repressed gene, normally expressed in hepatic progenitors, but re-expressed in hepatic cancer stem cells (hCSCs). Herein, we investigated the functional significance of EpCAM re-expression in HBV-mediated hepatocarcinogenesis.
Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study
Response-guided therapy has been confirmed to be an effective strategy for the treatment of chronic hepatitis C in the peginterferon (PegIFN) era, but no randomized trial utilizing this strategy has been conducted in chronic hepatitis B.
Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES
Statins are associated with delayed fibrosis progression and a reduced risk of hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV). Limited data exist regarding the most effective type and dose of statin in this population.